Background
==========

Women who inherit a germline mutation in the *BRCA2*gene are predisposed to breast cancer \[[@B1]\]. Therapies targeted specifically at these cancers have so far remained elusive. Recently, inhibition of poly-ADP-(ribose)-polymerase-1 (PARP-1) was shown to cause high levels of death in cells and xenografts deficient in BRCA2 \[[@B2]-[@B4]\].

Methods
=======

We have conditionally deleted *Brca2*and *p53*within murine mammary epithelium, resulting in the development of naturally arising tumours from 6 months of age. These tumours have been treated *in situ*with a highly potent inhibitor of PARP-1, either alone or in combination with carboplatin. The tumour size was followed by regular measurement with calipers.

Results
=======

Daily exposure to 50 mg/kg PARP-1 inhibitor caused significant regression or growth inhibition in the majority of *Brca2*/*p53*-deficient tumours, in comparison with *p53*-deficient or *pten*-deficient control tumours. Combination treatment with carboplatin did not enhance initial tumour regression compared with carboplatin treatment alone. However, prolonged treatment with PARP-1 inhibitor, after an initial 28-day combination therapy, increased the time to tumour relapse compared with 28 days of carboplatin monotherapy or combination therapy.

Conclusion
==========

This is the first preclinical study to show *in vivo*hypersensitivity of naturally arising *Brca2*-deficient mammary tumours to PARP-1 inhibition monotherapy and combination therapy.
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